Key facts
- Bibliographic identity is consistent across three databases: Neurology 2020, volume 95, issue 8, pages e1017-e1026, DOI 10.1212/WNL.0000000000010086, PMID 32571851, twelve authors led by Daniel D. Rhoads and ending with Brian S. Appleby.
- The center received 10,498 CSF specimens between May 2015 and April 2018.
- Accuracy was measured in 567 autopsy-verified cases: sensitivity 90.3 percent and specificity 98.5 percent.
- Sensitivity was lower for fatal familial insomnia, Gerstmann-Straussler-Scheinker disease, sporadic fatal insomnia, variably protease-sensitive prionopathy, and the VV1 and MM2 subtypes of sporadic CJD.
- Prion disease cases with a negative RT-QuIC were younger and had lower CSF tau and non-elevated 14-3-3 compared with RT-QuIC-positive cases.
- Sensitivity stayed high across the disease course, and some initially negative cases were positive on a later sample.
- Counting RT-QuIC-positive cases raised laboratory-based case ascertainment by about 90 percent compared with autopsy alone.
- The authors classify the evidence as Class III (patients screened for concerning symptoms); the abstract gives point estimates without confidence intervals.
- Authors are affiliated with the NPDPSC at Case Western Reserve University, Yale School of Public Health and CDC; funding was CDC grant NU38 CK000480.
Timeline
- 2015to 2018-04 Period over which the 10,498 CSF specimens were received.
- 2020Electronic publication.
- 2020Print issue date, Neurology 95(8).
Last checked 1 November 2026